Literature DB >> 28887099

Enhancing biopharmaceutical performance of an anticancer drug by long chain PUFA based self-nanoemulsifying lipidic nanomicellar systems.

Rajneet Kaur Khurana1, Sarwar Beg1, Andrea Julie Burrow2, Rakesh K Vashishta3, O P Katare1, Satvinder Kaur4, Prashant Kesharwani5, Kamalinder K Singh6, Bhupinder Singh7.   

Abstract

The aim of this study was to develop polyunsaturated fatty acid (PUFA) long chain glyceride (LCG) enriched self-nanoemulsifying lipidic nanomicelles systems (SNELS) for augmenting lymphatic uptake and enhancing oral bioavailability of docetaxel and compare its biopharmaceutical performance with a medium-chain fatty acid glyceride (MCG) SNELS. Equilibrium solubility and pseudo ternary phase studies facilitated the selection of suitable LCG and MCG. The critical material attributes (CMAs) and critical process parameters (CPPs) were earmarked using Placket-Burman Design (PBD) and Fractional Factorial Design (FFD) for LCG- and MCG-SNELS respectively, and nano micelles were subsequently optimized using I- and D-optimal designs. Desirability function unearthed the optimized SNELS with Temul <5min, Dnm <100nm, Rel15min >85% and Perm45min >75%. The SNELS demonstrated efficient biocompatibility and energy dependent cellular uptake, reduced P-gp efflux and increased permeability using bi-directional Caco-2 model. Optimal PUFA enriched LCG-SNELS exhibited distinctly superior permeability and absorption parameters during ex vivo permeation, in situ single pass intestinal perfusion, lymphatic uptake and in vivo pharmacokinetic studies over MCG-SNELS.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Bi-directional permeability; Docetaxel; Lymphatic uptake; Oral bioavailability; P-gp efflux; PUFA lipids; Quality by design

Mesh:

Substances:

Year:  2017        PMID: 28887099     DOI: 10.1016/j.ejpb.2017.09.001

Source DB:  PubMed          Journal:  Eur J Pharm Biopharm        ISSN: 0939-6411            Impact factor:   5.571


  5 in total

Review 1.  CD44-Targeted Nanocarrier for Cancer Therapy.

Authors:  Prashant Kesharwani; Rahul Chadar; Afsana Sheikh; Waleed Y Rizg; Awaji Y Safhi
Journal:  Front Pharmacol       Date:  2022-03-31       Impact factor: 5.810

2.  Pharmacokinetic studies of nanoparticles as a delivery system for conventional drugs and herb-derived compounds for cancer therapy: a systematic review.

Authors:  Omar Abdifetah; Kesara Na-Bangchang
Journal:  Int J Nanomedicine       Date:  2019-07-23

3.  Nebulised surface-active hybrid nanoparticles of voriconazole for pulmonary Aspergillosis demonstrate clathrin-mediated cellular uptake, improved antifungal efficacy and lung retention.

Authors:  Ranjot Kaur; Sarah R Dennison; Andrea J Burrow; Shivaprakash M Rudramurthy; Rajan Swami; Varun Gorki; O P Katare; Anupama Kaushik; Bhupinder Singh; Kamalinder K Singh
Journal:  J Nanobiotechnology       Date:  2021-01-11       Impact factor: 10.435

4.  Aerosolizable Lipid-Nanovesicles Encapsulating Voriconazole Effectively Permeate Pulmonary Barriers and Target Lung Cells.

Authors:  Ranjot Kaur; Sarah R Dennison; Shivaprakash M Rudramurthy; O P Katare; Teenu Sharma; Bhupinder Singh; Kamalinder K Singh
Journal:  Front Pharmacol       Date:  2022-03-10       Impact factor: 5.810

5.  Ionic co-aggregates (ICAs) based oral drug delivery: Solubilization and permeability improvement.

Authors:  Xianzi Zheng; Zhezheng Fang; Weizi Huang; Jianping Qi; Xiaochun Dong; Weili Zhao; Wei Wu; Yi Lu
Journal:  Acta Pharm Sin B       Date:  2022-04-26       Impact factor: 14.903

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.